(WELL) Welltower - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US95040Q1040

WELL: Housing, Health, Infrastructure, Properties, Communities, Care

Welltower Inc. (NYSE:WELL), a prominent S&P 500 constituent and real estate investment trust, is strategically headquartered in Toledo, Ohio. The company is at the forefront of transforming healthcare infrastructure, aligning its investments with leading operators in seniors housing, post-acute care, and health systems. This strategic approach facilitates the scaling of innovative care delivery models, enhancing overall wellness and healthcare experiences.

Welltowers portfolio is concentrated in high-growth urban markets across the United States, Canada, and the United Kingdom. Their assets encompass seniors housing, post-acute communities, and outpatient medical properties, reflecting a diverse and robust presence in the healthcare real estate sector. This geographic and segment diversification positions Welltower to capitalize on demographic trends such as aging populations and the increasing preference for outpatient care.

From a financial perspective, Welltower boasts a market capitalization of approximately $85.42 billion. The companys high P/E ratio of 87.38 and forward P/E of 76.92 suggest significant growth expectations. The price-to-book ratio of 2.77 indicates that investors value the companys assets higher than their book value, a point of interest for fund managers assessing valuation. The P/S ratio of 11.31 warrants consideration regarding revenue generation relative to assets.

For investors and fund managers, Welltowers strategic focus on major markets and diverse healthcare segments offers potential resilience against economic downturns, given healthcares defensive nature. However, the valuation metrics call for careful evaluation of growth prospects and profitability margins. Welltowers approach to healthcare infrastructure underscores its role in shaping the future of healthcare delivery, making it a noteworthy consideration for those invested in the sector.

Additional Sources for WELL Stock

WELL Stock Overview

Market Cap in USD 94,843m
Sector Real Estate
Industry REIT - Healthcare Facilities
GiC Sub-Industry Health Care REITs
IPO / Inception 2001-01-02

WELL Stock Ratings

Growth 5y 89.8%
Fundamental 33.7%
Dividend 51.3%
Rel. Strength 54.4
Analysts 4.05/5
Fair Price Momentum 187.79 USD
Fair Price DCF 69.27 USD

WELL Dividends

Dividend Yield 12m 1.89%
Yield on Cost 5y 6.50%
Annual Growth 5y -1.06%
Payout Consistency 97.5%

WELL Growth Ratios

Growth Correlation 3m 84.3%
Growth Correlation 12m 94.3%
Growth Correlation 5y 84.8%
CAGR 5y 30.60%
CAGR/Max DD 5y 0.75
Sharpe Ratio 12m 2.86
Alpha 59.50
Beta 1.191
Volatility 22.37%
Current Volume 2852.5k
Average Volume 20d 2941.4k
What is the price of WELL stocks?
As of March 31, 2025, the stock is trading at USD 153.42 with a total of 2,852,533 shares traded.
Over the past week, the price has changed by +2.39%, over one month by +1.25%, over three months by +23.36% and over the past year by +70.37%.
Is Welltower a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Welltower is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 33.71 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of WELL as of March 2025 is 187.79. This means that WELL is currently undervalued and has a potential upside of +22.4% (Margin of Safety).
Is WELL a buy, sell or hold?
Welltower has received a consensus analysts rating of 4.05. Therefor, it is recommend to buy WELL.
  • Strong Buy: 8
  • Buy: 5
  • Hold: 5
  • Sell: 1
  • Strong Sell: 0
What are the forecast for WELL stock price target?
According to ValueRays Forecast Model, WELL Welltower will be worth about 208.2 in March 2026. The stock is currently trading at 153.42. This means that the stock has a potential upside of +35.67%.
Issuer Forecast Upside
Wallstreet Target Price 162.5 5.9%
Analysts Target Price 145.5 -5.1%
ValueRay Target Price 208.2 35.7%